Genelux Corporation

GNLX · Nasdaq · United States

Share price · GNLX

$2.24-0.36 (-13.85%) 3M

close as of 2026-11-18 · 24h delayed · vol 801K (2.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GNLX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+12.0%
  2. 21 Oct 2026-17.2%
  3. 14 Oct 2026-7.9%
  4. 5 Aug 2026-11.0%
  5. 4 Aug 2026-5.4%
  6. 17 Jun 2026-5.9%
  7. 11 May 2026-6.8%
  8. 8 May 2026+9.9%
  9. 15 Apr 2026+7.6%

    Nothing announced by GNLX that day or the session before.

  10. 8 Jan 2026-19.8%

Share of unusual movement by asset

For each asset, the share of GNLX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
No discrete molecular targetOncolytic virus
Non-Small Cell Lung CancerOvarian Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Olvimulogene nanivacirepvecPhase 3Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer …
Est. primary completion 2026-12 · NCT05281471 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
Olvimulogene nanivacirepvecPhase 2Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma …
Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (14)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$6.5M$9.2M+ $9.5M short-term inv.$9.5M-$6.4M operating cash flowreport ↗
View 13 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$5.8M$9.3M+ $17M short-term inv.$8.9M-$6.1M operating cash flowreport ↗
2025-Q3—$4.7M$4.7M+ $16M short-term inv.$8.0M-$6.6M operating cash flowreport ↗
2025-Q2—$4.8M$6.5M+ $21M short-term inv.$7.5M-$7.1M operating cash flowreport ↗
2025-Q1—$4.7M$16M+ $19M short-term inv.$7.5M-$5.4M operating cash flowreport ↗
2024-Q3—$4.0M$6.1M+ $28M short-term inv.$6.5M-$5.8M operating cash flowreport ↗
2024-Q2—$4.4M$7.9M+ $26M short-term inv.$6.6M-$6.8M operating cash flowreport ↗
2024-Q1<$0.1M$4.0M$4.1M+ $16M short-term inv.$7.8M-$4.3M operating cash flowreport ↗
2023-Q3—$2.8M$30M$5.3M-$3.4M operating cash flowreport ↗
2023-Q2—$2.9M$27M$5.8M-$5.4M operating cash flowreport ↗
2023-Q1$0.2M$2.9M$10M$10M-$4.6M operating cash flowreport ↗
2022-Q3$11M$2.4M$1.4M—-$2.5M operating cash flowreport ↗
2022-Q2—$1.8M$4.2M$2.8M-$2.4M operating cash flowreport ↗
2022-Q1—$2.4M$7.2M$3.8M$2.8M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY<$0.1M$20M$5.3M$8.0M-$25M operating cash flowreport ↗

For fiscal year 2025, Genelux reported revenue of $0.01M, up 0.0% YoY, and R&D spend of $19.85M, up 4.5% YoY. Cash and equivalents stood at $5.33M, with a net loss of $32.15M and a quarterly net burn of $32.15M.

Genelux is advancing its lead oncolytic viral immunotherapy candidate, Olvi-Vec, through a Phase 3 registrational trial (OnPrime/GOG-3076) in platinum-resistant/refractory ovarian cancer, a Phase 2 trial (VIRO-25) in recurrent non-small cell lung cancer, and a Phase 1b/2 trial in recurrent small cell lung cancer in China. Initial interim results as of December 2025 data cutoffs showed a 60% disease control rate in five evaluable VIRO-25 patients and a 33% overall response rate (3/9 patients) in the SCLC trial, with Olvi-Vec generally well tolerated. Management anticipates reporting Phase 3 topline results in the second half of 2026 and updated dose-finding data throughout 2026, and the company continues its collaboration with Newsoara under a license agreement covering Olvi-Vec development in China.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY<$0.1M$19M$8.6M+ $22M short-term inv.$7.5M-$21M operating cash flowreport ↗
2023-FY$0.2M$13M$9.4M+ $14M short-term inv.$7.1M-$20M operating cash flowreport ↗
2022-FY$11M$9.1M$0.4M$1.3M-$3.6M operating cash flowreport ↗
2021-FY——$4.5M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 24 sales ($341K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03Yu Yong · Chief Scientific OfficerOpen-market sale668$2.01$1KForm 4
2026-11-03Zindrick Thomas · President and CEOOpen-market sale3,089$2.05$6KForm 4
2026-11-03Cappello Joseph · Chief Technical OfficerOpen-market sale668$2.04$1KForm 4
2026-08-31Yu Yong · Chief Scientific OfficerOpen-market sale9,683$2.75$27KForm 4
2026-08-31Zindrick Thomas · President and CEOOpen-market sale34,463$2.67$92KForm 4
2026-08-31Cappello Joseph · Chief Technical OfficerOpen-market sale10,257$2.74$28KForm 4
2026-08-04Zindrick Thomas · President and CEOOpen-market sale3,023$2.95$9KForm 4
2026-08-04Cappello Joseph · Chief Technical OfficerOpen-market sale653$2.95$2KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 70 reporting institutions held 9.3M shares ($23.3M, 20.5% of shares outstanding).

#InstitutionSharesValue
1WOODWARD DIVERSIFIED CAPITAL, LLC2,117,183$5.9M
2VANGUARD CAPITAL MANAGEMENT LLC1,695,480$4.1M
3Bleichroeder LP1,380,666$3.3M
4GEODE CAPITAL MANAGEMENT, LLC453,761$1.1M
5BlackRock, Inc.405,872$982K
6BANK OF AMERICA CORP /DE/323,865$784K
7FLPUTNAM INVESTMENT MANAGEMENT CO280,904$680K
8VANGUARD FIDUCIARY TRUST CO251,610$609K
9CM Management, LLC250,000$605K
10NORTHERN TRUST CORP164,456$398K
11Provident Wealth Management, LLC155,670$377K
12STATE STREET CORP145,850$353K
13LPL Financial LLC139,041$336K
14UBS Group AG122,579$297K
15OSAIC HOLDINGS, INC.119,008$288K